IL-17A disrupts the nasal mucosal epithelial barrier in patients with chronic rhinosinusitis by activating the ERK/STAT3 pathway. Wu H, Li Y, Li X, Huang W, et al. Rhinology 2024;62:726-738.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wu H, Li Y, Li X, Huang W, et al. IL-17A disrupts the nasal mucosal epithelial barrier in patients with chronic rhinosinusitis by activating the ERK/STAT3 pathway. Rhinology 2024;62:726-738.
PMID: 39365556